{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

A survey to understand the Insights on ACS Management, Perception & usAge of statins and Combinations of sTatins (IMPACT)

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif @if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Part A: Understanding the current perception & usage of high intensity statins in ACS & PCI.

  1. What is the proportion of patients with the following conditions in your clinical practice? *
    2. Diagnosis of patient % of patients Diagnosis of patient % of patients
    NSTEMI
    %
    STEMI
    %
    Unstable Angina
    %
  2. In your patients with ACS who are to undergo intervention, what is the LDL-C goal that you will target? *

  3. What proportion of ACS patient achieved more than 50% reduction in LDL-C after statin treatment? *

  4. To prepare a patient for intervention, which drugs are used as a loading dose? (Multiple options can be selected)*

  5. In what percentage of your patients do you use high intensity statins as a loading dose to PCI patients? *

  6. In which patient profiles you screen for apolipoprotein b? *

  7. Which of the following is your preferred statin and its loading dose prior to PCI. Please state the reason for the preference *

    		8.

  8. In your practice, which of the following patient profile do you prefer to initiate high intensity statin? *

  9. Which is your preferred statin for longer term statin therapy (three months after the primary cardiovascular event)? (Please specify dose used for the statin selected)*

  10. According to you, what are the clinical benefits of using a high intensity statin pre-treatment undergoing PCI? *

  11. Post PCI, which agents are prescribed to your patients for improved clinical outcomes? (Multiple options can be selected) *

  12. In post PCI patients, for how long do you recommend taking high-intensity statins? *

  13. In the event that your patients do not achieve their LDL-C goals even after statins, which will be your preferred agent to be added to attain LDL-C goal? *


    14. Part B : Understanding the usage of statin & combinations in the management of high-risk patients


  14. What is your choice of therapy in high-risk patients along with statins if LDL-C is above target? *

  15. Usually in your patients with ACS what is the duration of DAPT therapy that you usually prefer? *

  16. Post DAPT therapy, how long do you prefer anti-platelet monotherapy?

  17. In your patients with high bleeding risk what duration of initial DAPT do you usually prefer? *

  18. Which among the following do you prefer for anti-platelet monotherapy? *

  19. Despite high intensity statin therapy what percentage of your patients do not achieve LDL goals? *

  20. For secondary prevention patient who is on statin & LDL C levels are >100 mg/dL, what treatment strategy would you prefer? *
    21. Option 1 (Tick) Option 2 (Tick)
    Start with 20mg Rosuvastatin/ 20 mg Atorvastatin

    After 20mg Atorvastatin /20 mg Rosuvastatin

  21. After revascularization procedure how many patients have persistent angina? *

  22. For secondary prevention for how long do you recommend your patients to take high intensity statin? *

  23. In your high-risk secondary prevention patients with LDL-C above target even after high-intensity statin therapy what percentage of patients would you be keen to initiate?*

    		24.
    %

    %

    %
  24. What challenges do you face in intensification of statins in patients? *

  25. What percentage of patients on statins experience recurrent CV events within 1 year of previous event? *

  26. If the patient experiences a recurrent ASCVD event within 2 years after the first event, do you think an LDL-C goal below 40 mg/dL may be considered

  27. what % of your patients are diagnosed or suspected to be having Familial Hypercholesterolemia? *

  28. will you consider continuation of statin therapy if patients diagnosed with CKD are shifted to dialysis? *

  29. Please provide the details of management of dyslipidaemia for patients with eGFR < 30 mL/min per 1.73 m2? *
  30. In ACS patients if LDL-C goals are not achieved after statin treatment then will you increase the dose of statin or add another drug and why? *
  31. For primary prevention, how do you do risk assessment of patients in your clinical practice? *
  32. What percentage of your patients are on PCSK9 inhibitors? And what is the dose and frequency of it? *
  33. Do you administer statin + ezetimibe+ Bempedoic acid together to achieve the LDL- C target? *

  34. Do you think LDL-C goal below 40 mg/dL may be considered for the patients? *

  35. Do you recommend Coronary Artery Calcium (CAC) scoring in your patients and if yes then please provide the patient profiles? *